Cardiol Therapeutics Inc. Class A Common Shares (CRDL) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDL trades at $1.31 with a market cap of $147.55M and a P/E ratio of 0.00. CRDL moved +3.17% today. Year to date, CRDL is +30.00%; over the trailing twelve months it is +16.07%. Its 52-week range spans $0.77 to $2.24. Analyst consensus is buy with an average price target of $8.50. Rallies surfaces CRDL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Phase II MAvERIC Shows Sustained Pain, Inflammation Reductions; Phase III Enrollment Tops 75%: Cardiol Therapeutics reported that its Phase II MAvERIC study of CardiolRx achieved rapid, sustained reductions in pericarditis pain and inflammation, cutting recurrence rates with favorable safety. Results accepted by the Journal of the American Heart Association validate CardiolRx and bolster the ongoing Phase III MAVERIC trial, now over 75% enrolled.
| Metric | Value |
|---|---|
| Price | $1.31 |
| Market Cap | $147.55M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.24 |
| 52-Week Low | $0.77 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover CRDL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.50.